Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Aug 27, 2021
Distillery Therapeutics

PARIS farnesylation for Parkinson’s disease

BioCentury | Mar 16, 2018
Emerging Company Profile

Cirius safety

How Cirius’ insulin sensitizer could avoid AEs of Actos, Avandia in NASH
BioCentury | Apr 14, 2017
Finance

More NASH cash

Why investors are backing Cirius’ next-generation insulin sensitizer in NASH
BioCentury | Aug 6, 2007
Product Development

Sanitizing PPAR

BioCentury | Oct 23, 2006
Product Development

DPPs to the fore

BioCentury | Jul 3, 2006
Product Development

JNJ picks a PPAR

Items per page:
1 - 6 of 6